Lucid Diagnostics Inc.

NASDAQ:LUCD

Medical - Devices

Healthcare
$0.41 +3.80%

+$0.04 today

Market cap
$79.38M
Beta
1.08
P/E (TTM)
-2.3
EPS (TTM)
-$0.44
52W Low $0.90High $1.63

Volume 2.70M

Average 0.84M

LUCD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Lucid Diagnostics Inc.NASDAQ: LUCD

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $1.21M fell 15.5% year over year, behind the -7.8% change in trailing-twelve-month research & development. Sequentially, it fell 30.0% from the prior quarter. Over 3 fiscal years it compounded at +691.2% a year.

Context

  • Research & development amounted to 120654.5% of revenue in FY2025, up 120516.6 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -15.5% toward the trailing-twelve-month pace of -7.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.21M-30.0% QoQ
Last fiscal yearDec 2025
$5.68B+94659.7% YoY
LTMMar 2026
$5.46M-7.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.5%——
1 year+94659.7%——
3-year CAGR+691.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
5.68B USD
Year-over-year change
+94659.7%
4-year CAGR
+397.1%

Research & Development vs competitors

How LUCD compares with its peers on the latest reported figures

  • LUCD's LTM Mar 2026 research & development of $5.46M is the 8th highest of the 10 companies compared; the peer median is $20.18M.
  • Its year-over-year change of -7.8% is the 7th highest of 10, against a peer median of -5.9%.
  • Research & development amounts to 106.3% of revenue for LUCD, versus a peer median of 63.4%.
LUCD Competitors Peer median
Research & Development for LUCD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVRAnteris Technologies Global Corp.LTM Mar 2026$70.12M +24.4%+57.8%3788.3%
SEERSeer, Inc.LTM Mar 2026$41.33M -11.2%-6.2%274.8%
IRDOpus Genetics, Inc.LTM Mar 2026$33.44M +11.2%+29.0%279.0%
SCLXScilex Holding CompanyLTM Mar 2026$21.46M +138.8%+31.8%63.4%
RCELAVITA Medical, Inc.LTM Mar 2026$20.18M -5.9%+14.6%27.9%
OWLTOwlet, Inc.LTM Mar 2026$15.13M +46.7%-20.4%14.1%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$13.34M -7.2%+1.9%38.8%
LUCDLucid Diagnostics Inc.LTM Mar 2026$5.46M -7.8%+691.2%106.3%
APYXApyx Medical CorporationLTM Mar 2026$3.33M -25.7%-9.5%6.0%
STSSSkyAI, Inc.LTM Mar 2026$319.38K -20.4%-50.4%80.5%
Peer median (excluding LUCD) $20.18M-5.9%+1.9%63.4%

Competitors are the stored peer set for LUCD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue500K377K2.43M4.35M4.71M
Cost of Revenue585K3.61M8.48M8.27M7.54M
Gross Profit(85K)(3.24M)(6.05M)(3.92M)(2.84M)
Gross Margin-17.0%-858.6%-249.2%-90.2%-60.3%
Research & Development9.3M11.47M7.25M5.99M5.68B
Selling, General & Admin18.04M39.82M35.66M36.62B41.58B
Operating Expenses27.33M52.93M42.43M42.13M46.8M
Depreciation & Amortization4K1.94M2.5M1.17M872K
EBITDA(27.42M)(54.23M)(49.75M)(44.34M)(57.12M)
EBITDA Margin-5483.0%-14383.8%-2049.1%-1020.2%-1213.7%
Operating Income(27.42M)(56.17M)(48.48M)(46.05M)(49.64M)
Operating Margin-5483.8%-14899.5%-1996.8%-1059.6%-1054.8%
Interest Income088K424K322K386K
Interest Expense659K8K416K26K22K
Other Income / Expenses(659K)0(4.18M)523K(8.37M)
Income Before Tax(28.08M)(56.17M)(52.67M)(45.53M)(58.01M)
Pre-Tax Margin-5615.6%-14899.5%-2169.1%-1047.6%-1232.7%
Income Tax Expense00000
Net Income(28.08M)(56.17M)(52.67M)(45.53M)(58.01M)
Net Margin-5615.6%-14899.5%-2169.1%-1047.6%-1232.7%
EPS (Basic)(0.78)(1.55)(1.26)(1.05)(0.69)
EPS (Diluted)(0.78)(1.55)(1.26)(1.05)(0.69)
Weighted Avg Shares36.06M36.17M41.76M50.52M101.95M
Weighted Avg Shares (Diluted)36.06M36.17M41.76M50.52M101.95M

Lucid Diagnostics Inc.

NASDAQ:LUCD

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.